Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2)

RA Otten, DK Smith, DR Adams, JK Pullium… - Journal of …, 2000 - Am Soc Microbiol
RA Otten, DK Smith, DR Adams, JK Pullium, E Jackson, CN Kim, H Jaffe, R Janssen…
Journal of virology, 2000Am Soc Microbiol
Postexposure prophylaxis (PEP) after intravaginal exposure to human immunodeficiency
virus (HIV) was investigated using the HIV type 2 (HIV-2)/pig-tailed macaque transmission
model. PEP for 28 days with the reverse transcriptase inhibitor (R)-9-(2-
phosphonylmethoxypropyl) adenine (PMPA; tenofovir) was initiated 12 to 72 h following HIV-
2 exposure. Systemic infection was not evident in the 12-and 36-h groups, as defined by
plasma viremia, cell-associated provirus, antibody responses, and lymph node virus …
Abstract
Postexposure prophylaxis (PEP) after intravaginal exposure to human immunodeficiency virus (HIV) was investigated using the HIV type 2 (HIV-2)/pig-tailed macaque transmission model. PEP for 28 days with the reverse transcriptase inhibitor (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA; tenofovir) was initiated 12 to 72 h following HIV-2 exposure. Systemic infection was not evident in the 12- and 36-h groups, as defined by plasma viremia, cell-associated provirus, antibody responses, and lymph node virus. Breakthrough infection in the 72-h group was detected at week 16 post-virus exposure. These results demonstrate for the first time using a vaginal transmission model that early intervention after high-risk sexual exposures may prevent infection.
American Society for Microbiology